Skip Navigation



Home » Drug Information » FDA Approved Drugs » 1998
Medical Areas: Hematology | Oncology

View By:YearCompanyConditionsTherapeutic AreasDrug Names


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Amgen
Approval Status: Approval April 1998
Treatment Area: slow white blood cell recovery following chemotherapy

General Information

Neupogen has been approved for its fifth indication: to reduce the time to neutrophil recovery and the duration of fever following chemotherapy treatment in patients being treated for acute myeologenous leukemia. Patients with this type of leukemia can now receive Neupogen to improve their ability to tolerate essential chemotherapy treatments.